Clobetasol propionate eye drops for postoperative inflammation, pain now available in US
Click Here to Manage Email Alerts
Clobetasol propionate ophthalmic suspension 0.05% for postoperative inflammation and pain after ocular surgery is now commercially available in the U.S., according to a press release from Eyenovia.
“The commercial launch of clobetasol represents a significant milestone for our company, and as the first new ophthalmic steroid to be approved in more than 15 years, a meaningful advancement in the field of ocular surgery,” Michael Rowe, the company’s CEO, said in the release. “With its efficacy and safety profile, convenient twice-a-day dosing regimen and streamlined distribution that is designed to eliminate complications from insurance, we believe clobetasol will generate strong interest among eye doctors.”
The formulation, which was approved by the FDA in March, demonstrated a “strong level of interest” among 100 ophthalmic surgeons recently surveyed, the company stated, with respondents ranking efficacy as the most important factor of a postoperative steroid.
According to the release, clinical studies have shown that about 80% of patients on clobetasol experienced complete pain relief 4 days after surgery compared with 50% given vehicle.
As Healio previously reported, Eyenovia acquired the exclusive rights for APP13007, the investigational precursor to clobetasol, from Formosa Pharmaceuticals in August 2023.
“This commercial U.S. launch of clobetasol has been much anticipated and we are excited to provide this formidable therapy to ocular surgery patients in the U.S. with our partner, Eyenovia,” Erick Co, PhD, Formosa’s president and CEO, said in the release.
Read more about
Click Here to Manage Email Alerts